The FDA has approved Auvelity (dextromethorphan HBr/bupropion HCl) for Alzheimer disease agitation, providing a non-antipsychotic option based on ADVANCE-1 and ACCORD-2 data.

Higher vitamin D levels in early midlife are associated with lower tau deposition in later midlife among adults without dementia.

There is a greater risk for the development of behavioral problems among children born with congenital heart disease.

The FDA is testing real-time clinical trial reporting in an effort to speed up the drug review and approval process.

Recent data show high interest and use of spiritual practices and manual therapies among older individuals, particularly those with depression.

What were the most significant improvements seen in the Myasthenia Gravis-Activities of Daily Living and Quantitative ...

Adenotonsillectomy appears to be an effective way to resolve obstructive sleep apnea and improve sleep efficacy for many children.

Eptinezumab plus education reduces monthly migraine days in adults with chronic migraine and medication-overuse headache.

FDA issues a Complete Response Letter to Grace Therapeutics for GTx-104, an intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage.

Cognitive function may deteriorate preceding cardiovascular events among older adults, highlighting the value of early cognitive screening.

Tavapadon significantly improves motor function and activities of daily living in adults with early Parkinson disease compared with placebo.

The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and adult patients with OTOF-related sensorineural hearing loss.